Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
6.74M
-
Shares change
-
-627K
-
Total reported value, excl. options
-
$11.2M
-
Value change
-
-$1.1M
-
Number of buys
-
8
-
Number of sells
-
-8
-
Price
-
$1.66
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q1 2023
21 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q1 2023.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.74M shares
of 26M outstanding shares and own 25.9% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (3.07M shares), Redmile Group, LLC (2.07M shares), Bruce & Co., Inc. (672K shares), AXA S.A. (226K shares), Artal Group S.A. (200K shares), SILVERARC CAPITAL MANAGEMENT, LLC (140K shares), Alpha Wave Global, LP (120K shares), CANTOR FITZGERALD, L. P. (53.3K shares), PNC Financial Services Group, Inc. (50K shares), and BANK OF AMERICA CORP /DE/ (32.2K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.